We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+26.72%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.13B
AUM Growth
+$109M
Cap. Flow
-$57.7M
Cap. Flow %
-5.12%
Top 10 Hldgs %
41.36%
Holding
140
New
44
Increased
20
Reduced
33
Closed
30

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$38.4M
2
LLY icon
Eli Lilly
LLY
+$37.9M
3
ONCR
Oncorus, Inc.
ONCR
+$20.9M
4
SGTX
Sigilon Therapeutics, Inc. Common Stock
SGTX
+$19.8M
5
CCCC icon
C4 Therapeutics
CCCC
+$12.9M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$56.2M
2
ABBV icon
AbbVie
ABBV
+$43.2M
3
AMGN icon
Amgen
AMGN
+$28M
4
FOLD
Amicus Therapeutics
FOLD
+$20M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 67.85%
2 Technology 8.78%
3 Industrials 3.15%
4 Consumer Discretionary 1.89%
5 Communication Services 0.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVS icon
26
CALL
Novartis
NVS
$297B
$11.3M 1.01%
+120,000
New +$10.5M
BBIO icon
27
BridgeBio Pharma
BBIO
$15.7B
$11.2M 1%
+157,900
New +$7.62M
META icon
28
Meta Platforms (Facebook)
META
$1.42T
$10.9M 0.97%
39,998
+4,998
+14% +$1.37M
MRK icon
29
CALL
Merck
MRK
$322B
$10.6M 0.94%
+136,240
New +$10.4M
MSFT icon
30
Microsoft
MSFT
$3.45T
$10.6M 0.94%
47,536
-3,742
-7% -$805K
CLDX icon
31
Celldex Therapeutics
CLDX
$2.99B
$10.5M 0.93%
597,198
+227,198
+61% +$4.09M
ZNTL icon
32
Zentalis Pharmaceuticals
ZNTL
$337M
$9.91M 0.88%
190,796
-4,200
-2% -$189K
ALXN
33
DELISTED
Alexion Pharmaceuticals
ALXN
$9.37M 0.83%
+60,000
New +$7.71M
TRIL
34
DELISTED
Trillium Therapeutics Inc.
TRIL
$9.22M 0.82%
626,759
-18,676
-3% -$269K
KYMR icon
35
Kymera Therapeutics
KYMR
$8.51B
$9.16M 0.81%
147,700
-12,300
-8% -$600K
BURL icon
36
Burlington
BURL
$23.2B
$9.15M 0.81%
35,000
– –
TECX
37
Tectonic Therapeutic
TECX
$529M
$9.14M 0.81%
54,656
+27,531
+101% +$4.89M
VRNS icon
38
Varonis Systems
VRNS
$4.59B
$9.04M 0.8%
165,675
-15,000
-8% -$651K
IMTX icon
39
Immatics
IMTX
$1.18B
$8.88M 0.79%
823,391
+23,391
+3% +$247K
CAMT icon
40
Camtek
CAMT
$6.18B
$8.76M 0.78%
+400,000
New +$7.66M
NBP
41
NovaBridge Biosciences American Depositary Shares
NBP
$185M
$8.57M 0.76%
181,820
– –
VRNT
42
DELISTED
Verint Systems
VRNT
$8.53M 0.76%
+249,301
New +$7.08M
COGT icon
43
Cogent Biosciences
COGT
$6.65B
$8.26M 0.73%
+735,434
New +$8.08M
SPRY icon
44
ARS Pharmaceuticals
SPRY
$509M
$8.07M 0.72%
+174,261
New +$5.82M
TEVA icon
45
Teva Pharmaceuticals
TEVA
$40.8B
$8.04M 0.71%
832,878
-750,000
-47% -$7.18M
IMVT icon
46
Immunovant
IMVT
$7.93B
$7.85M 0.7%
170,000
– –
QURE icon
47
uniQure
QURE
$3.03B
$7.8M 0.69%
216,000
+90,000
+71% +$3.8M
RPTX
48
DELISTED
Repare Therapeutics
RPTX
$7.69M 0.68%
224,300
-20,700
-8% -$618K
FATE icon
49
Fate Therapeutics
FATE
$286M
$7.46M 0.66%
82,000
-106,000
-56% -$6.58M
BYSI icon
50
BeyondSpring
BYSI
$47.3M
$7.3M 0.65%
+598,000
New +$7.86M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2020 Portfolio in Review

As of Q4 2020, Sphera Funds Management held 140 positions worth $1.13B, up 11% from $1.02B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Sphera Funds Management withdrew a net $57.7M in Q4 2020, closing 30 positions and reducing 33 holdings. Its most notable exit was Sanofi, an estimated $56.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 70% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Bristol-Myers Squibb worth $38.8M.

  • Sphera Funds Management's largest Q4 2020 buy was Bristol-Myers Squibb: 625,000 shares worth $38.8M.
  • Sphera Funds Management added most to Eli Lilly in Q4 2020, an estimated $37.9M increase.
  • Sphera Funds Management's biggest Q4 2020 reduction was AbbVie, cutting an estimated $43.2M.
  • Sphera Funds Management fully exited Sanofi in Q4 2020, selling an estimated $56.2M.
  • Sphera Funds Management's ten largest holdings make up 41% of its $1.13B portfolio in Q4 2020.
  • Sphera Funds Management opened 44 new positions and closed 30 in Q4 2020.
  • Sphera Funds Management's portfolio value rose 11% quarter-over-quarter to $1.13B.

Based on Sphera Funds Management's 13F filing for Q4 2020, filed 16 Feb 2021.